Blanca Rebeca Ibarra Ibarra

Blanca Rebeca Ibarra Ibarra

Auto-generated profile, based on publicly available information

Blanca Rebeca Ibarra Ibarra

Instituto Nacional de Cardiología Ignacio Chávez

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
IPIsrael Pérez-Torres
Israel Pérez-Torres
BIBlanca Ibarra
Blanca Ibarra
Elizabeth Soria-CastroElizabeth Soria-Castro
Elizabeth Soria-Castro
RTRocío Torrico-Lavayen
Rocío Torrico-Lavayen
NPNatalia Pavón Pavón
Natalia Pavón Pavón
GBGuadalupe Baños
Guadalupe Baños
The kidneys are organs that can be severely impaired by metabolic syndrome (MS). This is characterized by the association of various pathologies such as hypertension, dyslipidemia, and type-2 diabetes. Glycine, a nonessential amino acid, is known to possess various protective effects in the kidney, such as a decrease in the deterioration of renal function and a reduction of the damage caused by hypoxia. In a rat model of MS, the effect of glycine on the cyclooxygenase (COX) pathway of arachidonic acid (AA) metabolism was studied in isolated perfused kidney. MS was induced in Wistar rats by feeding them a 30% sucrose solution for 16 weeks. The addition of 1% glycine to their drinking water containing 30% sucrose, for 8 weeks, reduced high blood pressure, triglyceride levels, insulin concentration, homeostatis model assessment (HOMA) index, albuminuria, AA concentration in kidney homogenate, renal perfusion pressure, prostaglandin levels, PLA2expression, and COX isoform expression, compared with MS rats that did not receive the glycine supplement. Glycine receptor expression decreased significantly with MS, but glycine treatment increased it. The results suggest that in the MS model, 1% glycine treatment protects the kidney from damage provoked by the high sucrose consumption, by acting as an anti-inflammatory on the COX pathway of AA metabolism in kidney.

1 April 2019 in Stem Cells International
Verified
Journal Article
Open access
PDF file
BIBlanca Rebeca Ibarra-Ibarra
Blanca Rebeca Ibarra-Ibarra
MFMartha Franco
Martha Franco
APAraceli Paez-Arenas
Araceli Paez-Arenas
EVELVIRA VARELA
ELVIRA VARELA
FMFelipe Masso
Felipe Masso
Cell-based therapy has become a resource for the treatment of cardiovascular diseases; however, there are some conundrums to achieve. In vitro cardiomyocyte generation could be a solution for scaling options in clinical applications. Variability on cardiac differentiation in previously reported studies from adipose tissue-derived mesenchymal stem cells (ASCs) and the lack of measuring of the cardiomyocyte differentiation efficiency motivate the present study. Here, we improved the ASC-derived cardiomyocyte-like cell differentiation efficiency with a directed cardiomyocyte differentiation protocol: BMP-4 + VEGF (days 0-4) followed by a methylcellulose-based medium with cytokines (IL-6 and IL-3) (days 5-21). Cultures treated with the directed cardiomyocyte differentiation protocol showed cardiac-like cells and “rosette-like structures” from day 7. The percentage of cardiac troponin T- (cTnT-) positive cells was evaluated by flow cytometry to assess the cardiomyocyte differentiation efficiency in a quantitative manner. ASCs treated with the directed cardiomyocyte differentiation protocol obtained a differentiation efficiency of up to 44.03% (39.96%±3.78) at day 15 without any enrichment step. Also, at day 21 we observed by immunofluorescence the positive expression of early, late, and cardiac maturation differentiation markers (Gata-4, cTnT, cardiac myosin heavy chain (MyH), and the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCa2)) in cultures treated with the directed cardiomyocyte differentiation protocol. Unlike other protocols, the use of critical factors of embryonic cardiomyogenesis coupled with a methylcellulose-based medium containing previously reported cardiogenic cytokines (IL-6 and IL-3) seems to be favorable for in vitro cardiomyocyte generation. This novel efficient culture protocol makes ASC-derived cardiac differentiation more efficient. Further investigation is needed to identify an ASC-derived cardiomyocyte surface marker for cardiac enrichment.

14 January 2026 in Acta Pediátrica de México
Verified
Journal Article
Open access
PDF file
BIBlanca Rebeca Ibarra Ibarra
Blanca Rebeca Ibarra Ibarra
DMDorian Karitina Olmos Morfin
Dorian Karitina Olmos Morfin
INTRODUCCIÓN: Las distrofias-distroglicanopatías musculares congénitas causadas por variantes genéticas patogénicas en el gen de la proteína relacionada a Fukutina (FKRP) son un grupo de enfermedades neuromusculares raras. Estas se caracterizan por una expresividad variable que oscila entre fenotipos leves a graves con presencia de hipotonía, distrofia muscular proximal con o sin manifestaciones extra musculares como alteraciones del sistema nervioso central (SNC), alteraciones oftalmológicas y/o discapacidad intelectual. PRESENTACIÓN DE CASO: Paciente pediátrico con fenotipo compatible con una distrofia muscular congénita con hipotonía en la etapa lactante, debilidad muscular proximal, retraso del desarrollo motor y del lenguaje, elevación de creatincinasa, pseudohipertrofia de gastrocnemios y anormalidades estructurales del SNC. Por medio de una prueba de secuenciación de un panel de genes, se identificó la presencia de dos variantes patogénicas en estado homocigoto en el gen NM_024301.4 FKRP c.1387A>G (p. Asn463Asp) correspondiente a una distrofia-distroglicanopatía muscular congénita sin discapacidad intelectual tipo B5 autosómica recesiva. La variante identificada presenta un efecto fundador en la población mexicana con pocos casos reportados previamente. Hasta el momento, el presente es el primer caso reportado con las variantes antes mencionadas y anormalidades estructurales en el SNC. Además, se identificaron dos variantes genéticas benignas asociadas a pseudodeficiencia alélica del gen de la alfa-glucosidasa ácida (GAA). CONCLUSIONES: En pacientes con distrofias musculares de inicio temprano que presentan manifestaciones extra musculares, se debe sospechar en distrofias-distroglicanopatías. El uso de la secuenciación de paneles de genes o exoma como primer abordaje, aunado a la valoración por genética, puede reducir la odisea diagnóstica.